Relationship between polymorphism of peroxisome proliferation-activated receptor-gamma C161T gene and chronic kidney disease

LIU Feng,ZHANG Xintian,QI Hualin,ZHANG Ruiqing,JIANG Wei,YU Chen,YAN Haidong
2009-01-01
Abstract:Objective To investigate the relationship between polymorphism of peroxisome proliferation-activated receptor-gamma (PPARγ) C161T gene and chronic kidney disease (CKD). Methods Ninety-one patients with CKD (according to NKF/DOQI) and 149 healthy controls were included in the present study. PPARγC161T gene polymorphism was detected by polymerase chain reaction(PCR)-direct sequencing assay. Moreover, the blood pressure, body mass index(BMI),urine albumin/urine creatinine(ACR), 24 h urine protein, serum creatinine, blood glucose, blood lipoprotein, and glomerular filtration rate and were examined in all the subjects. The relationship of PPARγC161T genotype frequencies and the allele frequencies with the clinical and laboratory data was analyzed. Results ① There was no significant difference in the frequencies of CC, TC+TT genotypes and C, T allele frequencies between the CKD and normal control groups (All P>0.05). ② In the CKD group, the frequencies of PPARγTC+TT genotype and "T" allele in patients with bulk proteinuria were significantly higher than those with no bulk proteinuria (both P<0.05). The frequencies of PPARγC161T gene polymorphism was not significantly different between patients of CKD1 and CKD2-5 stages (both P>0.05) . ③ In the CKD group,there was no significant difference in BMI values, fasting blood glucose, blood pressure, urine protein in 24 hours, total triglyeride, or high-density lipoproteins between the patients with CC genotype and CT+TT genotype (all P>0.05). The levels of serum creastinine, total cholesterol, and low-density lipoproteins in the patients with CC genotype were significantly higher than those in the patients with CT+TT genotype (all P<0.05). Conclusion PPARγ C161T gene polymorphism is significantly associated with the development and severity of CKD, and "T" allele carriers are at higher risk of CKD.
What problem does this paper attempt to address?